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Introduction: The objective of this study was to describe the pharmacokinetics of vancomycin in ICU patients
and to examine whether contemporary antibiotic dosing results in concentrations that have been associated with
favourable response.
Methods: The Defining Antibiotic Levels in Intensive Care (DALI) study was a prospective, multicentre
pharmacokinetic point-prevalence study. Antibiotic dosing was as per the treating clinician either by intermittent
bolus or continuous infusion. Target trough concentration was defined as ≥15 mg/L and target pharmacodynamic
index was defined as an area under the concentration-time curve over a 24-hour period divided by the minimum
inhibitory concentration of the suspected bacteria (AUC0–24/MIC ratio) >400 (assuming MIC ≤1 mg/L).
Results: Data of 42 patients from 26 ICUs were eligible for analysis. A total of 24 patients received vancomycin
by continuous infusion (57%). Daily dosage of vancomycin was 27 mg/kg (interquartile range (IQR) 18 to 32), and
not different between patients receiving intermittent or continuous infusion. Trough concentrations were highly
variable (median 27, IQR 8 to 23 mg/L). Target trough concentrations were achieved in 57% of patients, but more
frequently in patients receiving continuous infusion (71% versus 39%; P = 0.038). Also the target AUC0–24/MIC ratio
was reached more frequently in patients receiving continuous infusion (88% versus 50%; P = 0.008). Multivariable
logistic regression analysis with adjustment by the propensity score could not confirm continuous infusion as an
independent predictor of an AUC0–24/MIC >400 (odds ratio (OR) 1.65, 95% confidence interval (CI) 0.2 to 12.0) or
a Cmin ≥15 mg/L (OR 1.8, 95% CI 0.4 to 8.5).
Conclusions: This study demonstrated large interindividual variability in vancomycin pharmacokinetic and
pharmacodynamic target attainment in ICU patients. These data suggests that a re-evaluation of current
vancomycin dosing recommendations in critically ill patients is needed to more rapidly and consistently achieve
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Methicillin-resistant Staphylococcus aureus (MRSA) has
become a major pathogen in severe healthcare-associated
infections [1]. In the past decades, the anti-MRSA arma-
mentarium has broadened. Still, vancomycin remains the
most common first-line option for treating severe infec-
tions with parenteral therapy [2]. Achievement of pharma-
cokinetic/pharmacodynamic (PK/PD) indices associated
with maximal bacterial kill is recommended to increase
the likelihood of clinical cure. To achieve target serum
concentrations in life-threatening infections such as sepsis,
infective endocarditis, osteomyelitis and hospital-acquired
pneumonia, current guidelines recommend trough serum
concentrations of vancomycin (Cmin) ranging 15 to 20 mg/L
[3]. Such serum concentrations should achieve an area
under the concentration-time curve over a 24-hour period
divided by the minimum inhibitory concentration of the
suspected bacteria (AUC0–24/MIC ratio) of >400 (assum-
ing an MIC ≤1 mg/L). This threshold was significantly
associated with favourable clinical and bacteriological out-
comes in patients with lower respiratory tract infections
and therefore generally accepted as the appropriate
PK/PD target [4]. Other investigators confirmed that
an AUC0–24/MIC ratio for optimizing clinical outcomes
should be at least 400 [5,6].
In critically ill patients with severe sepsis or septic
shock however, target concentrations may be difficult to
achieve due to the increased distribution volume and
the presence of augmented renal clearance (ARC) [7-9].
These factors may lead to reduced trough concentrations
and underdosing, leading to inadequate bacterial killing
and possible treatment failure. Moreover, insufficient
dosing may facilitate development of multidrug resist-
ance. As vancomycin is renally cleared and distributes
widely throughout the body, its pharmacokinetics may be
altered from the pathophysiological alterations inherent to
sepsis. Furthermore, these factors imply great interindivid-
ual variability in pharmacokinetics complicating accurate
prediction of serum concentrations in septic patients.
Alternatively, the course of ICU patients may be
complicated by acute kidney injury (AKI), in which
case decreased vancomycin clearance and subsequent
increased trough concentrations may cause toxicity. Should
AKI worsen, renal replacement therapy (RRT) may be
required with drug clearance varying according to mode of
RRT, dose of RRT delivered, filter material and surface
area, and blood flow rate [10,11]. As such, factors that may
lead to underdosing as well as overdosing are to be consid-
ered. The above-mentioned conditions call for an altered
dosing approach in critically ill patients compared with
mild-to-moderately ill patients [12-14]. Several investiga-
tors reported on pharmacokinetics of vancomycin in
critically ill patients [5,6,15,16] but most studies are
single centre designs and there is no insight incurrent practice - and therefore in pharmacokinetics
variability - across ICUs.
The objective of this study was to describe the
pharmacokinetics of vancomycin in critically ill patients
and to examine whether contemporary antibiotic dosing
for ICU patients achieves concentrations that are associ-
ated with favourable response in previous reports. We
hypothesised that vancomycin target trough concentra-
tions and AUC0–24/MIC are frequently not achieved and
demonstrate considerable variability in critically ill pa-
tients. Furthermore, we investigated the role of continuous
infusion of vancomycin. We also studied factors associ-
ated with favourable pharmacokinetic outcome (trough
concentration ≥15 mg/L and AUC0–24/MIC ratio >400).
Methods
Study design
The Defining Antibiotic Levels in Intensive Care (DALI)
study was a prospective, multicentre pharmacokinetic
point-prevalence study. For detailed information on me-
thods we refer the reader to the protocol of DALI study
that has been previously published [17]. In this secondary
study patients receiving intravenous vancomycin, intermit-
tently or continuously, were analysed.
Patients
Critically ill adult patients were all identified for partici-
pation by clinical ICU staff on the Monday of the nomi-
nated sampling week, with blood sampling and data
collection occurring throughout that week. Ethical ap-
proval to participate in this study was obtained at all
participating centres and informed consent was obtained
from each patient or their legally authorised representa-
tive. The lead site was The University of Queensland,
Australia with ethical approval granted by the Medical
Research Ethics Committee (no. 201100283, May 2011).
The contributing authors are listed in Additional file 1
and the sites and their ethical approval bodies are listed
in Additional file 2.
Intervention
Antibiotic dosing was as per the treating clinician and
therapy could be administered by either intravenous
intermittent or continuous infusion. Each patient had
two blood samples taken: for intermittent administration
of vancomycin, blood sample A was a mid-dose blood
sample at 50% of the way through a dosing interval and
blood sample B was a pre-dose concentration at the end
of a dosing interval (within 30 minutes of the next dose),
while for continuous administration sample A was at
any time and sample B was >6 hours after sample A. The
observed concentrations were then interpreted in relation
to a presumed MIC of 1 mg/L.
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Data collection was performed by trained staff at each
participating centre and entered onto a case report form
(CRF). Various demographic and clinical data were col-
lected, including age, gender, height, weight, admission
diagnosis, presence of extracorporeal circuits (for example
RRT), clinical outcome of infection, presence/absence of
surgery within previous 24 hours, and mortality at 30 days.
Also, organ function data (including renal function -
serum creatinine concentration during studied dosing in-
terval; eight-hour urinary creatinine clearance (where
available), fluid balance for total length of stay and previ-
ous 24 hours), antibiotic dosing (dose and frequency, time
of dosing and sampling, day of antibiotic therapy), and
infection data (including known or presumed pathogen)
were collected.
Antibiotic dosing data including the dose, infusion
duration, frequency of administration, the time of dosing
and sampling and the day of antibiotic therapy were col-
lected. All data were collated by the coordinating centre
(Burns, Trauma and Critical Care Research Centre, The
University of Queensland, Australia).
Bioanalysis
Blood samples were processed and stored per protocol
to maintain integrity. Vancomycin concentrations in
serum were determined by a validated chromatographic
assay method on an Applied Biosystems API2000 mass
spectrometer (Applied Biosystems, Foster City, CA, USA)
with Shimadzu high-performance liquid chromatography
(HPLC) system (Shimadzu Corp., Kyoto, Japan). The sta-
tionary phase was a Waters X-Terra C18 column (5 μm,
150 × 2.1 mm) (Waters Corp., Milford, MA, USA) and the
mobile phase was a gradient (between 20% and 95% or-
ganic) of methanol containing 10 mM heptafluorobutyric
acid (HFBA) with 0.1% formic acid containing 10 mM
HFBA. Vancomycin and the internal standard (tobramycin)
were detected using multiple reaction monitoring (MRM)
scans in positive ion detection mode with electrospray
ionisation (ESI) sample introduction. Vancomycin stan-
dards and quality controls were prepared in serum. One
hundred microlitres of sample was mixed with the internal
standard and the sample then de-proteinated with aceto-
nitrile and lipids removed with dichloromethane before
injection. The method fitted a quadratic regression profile
from 0.1 to 100 μg/mL. Accuracy and precision were deter-
mined from quality controls at high, medium and low
concentrations and were within 10% at all levels. These
methods are in accordance with the US Food and Drug
Administration’s guidance for industry on bioanalysis [18].
Pharmacokinetic analyses
The pharmacokinetic values were calculated using non-
compartmental methods. The apparent terminal eliminationrate constant (kel) was determined from log-linear least
squares regression analysis of concentrations from sample
A and B. For intermittent infusions, the maximum con-
centration for the dosing period (Cmax) was calculated
using the following equation:
Cmax ¼ C0= 1–e−kel:τ
 
Where C0 is the concentration at sample A and τ is
the dosing interval in hours. The minimum concentra-
tion for the dosing period (Cmin) was the observed value.
Half-life (T1/2) was calculated as ln(2)/z. The area under the
concentration time curve from 0 to 12 hours (AUC0–12)
was calculated using the linear trapezoidal rule with the
derived Cmax estimate. The AUC from 0 to 24 hours
(AUC0–24) was calculated using a doubling of AUC0–12
with pharmacokinetic steady-state assumed for all patients.
For patients receiving continuous infusion, the AUC0–24
was calculated using the average of concentrations for sam-
ple A and B multiplied by 24 hours. Vancomycin clearance
(CL) was calculated using the equation dose/AUC0–12.
The AUC0–24/MIC ratio was calculated by dividing the
AUC0–24 by MICs 0.5, 1 and 2 mg/L.
Outcome variables
Vancomycin trough concentrations and AUC0–24/MIC
ratios are the main PK/PD variables. The target trough
concentration is defined as ≥15 mg/L and the target
AUC0–24/MIC ratio is defined as >400.
Statistical analyses
Basic statistics on demographic, clinical and PK/PD
related data were presented by number (%), median
[1st-3rd quartile] or mean (standard deviation (SD)) as
appropriate. Chi-square and Mann-Whitney U test were
used as appropriate. Logistic regression analysis was used
to assess unadjusted associations with the target PD index
(AUC0–24/MIC ratio >400) or target trough concentration
(≥15 mg/L) and independent variables. Various clinical
and demographic factors were evaluated for entering into
the model. Multivariable logistic regression was used to
assess relationships between continuous infusion of van-
comycin and the target PD index. In these analyses
adjustment for covariates was obtained by means of a
propensity score estimated for each subject on basis
of a logistic regression of treatment (continuous or inter-
mittent infusion) received on covariates. The propensity
score represents a single variable reflecting the effect of
the covariants on the probability of receiving continuous
infusion. It summarises covariates with a statistical or
plausible relationship with continuous infusion therapy or
serum concentrations. Covariates used in the final pro-
pensity model were age, gender, sequential organ failure
assessment (SOFA) score, RRT, fluid balance, vancomycin
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on therapy. The area under the curve, representing the
probability that the patient would receive continuous infu-
sion based on the variables included, was 0.82 (95% confi-
dence interval (CI) 0.68 to 0.96). Results of the regression
analyses are reported as odds ratios (OR) and 95% CI. The
Hosmer-Lemeshow test was used to assess whether or not
the observed event rates match expected event rates in
subgroups of the model population. Statistical significance
was defined as P <0.05.
Results
Vancomycin blood samples were collected from 45 critic-
ally ill patients. Three patients were excluded as their sam-
ples were not viable. As such, the study sample consisted
of 42 study subjects from 26 ICUs of eight countries
(Andorra, Belgium, Spain, UK, Greece, Italy, Portugal,
Turkey). Demographic data, disease severity, and renal
function are described in Table 1. Data are presented for
patients receiving intermittent versus continuous vanco-
mycin therapy. Vancomycin was given empirically in 31
patients (73.8%). Therapy was targeted in only 11 patients.
MICs for isolated Staphylococcus spp. were only reported
in two cases (both MIC 1 mg/L).
Data on dosing, pharmacokinetics and PK/PD are re-
ported in Table 2. Twenty-four patients received vanco-
mycin by continuous infusion (57.1%). The average daily
dosage of vancomycin was 27 (SD 13) mg/kg and was
not different between patients in the continuous infusion
and intermittent dosing group. No difference was ob-
served in daily dosing between patients receiving RRT or
with different glomerular filtration rates (GFRs) (Figure 1)
(P = 0.359).
Target trough concentrations (≥15 mg/L) were achieved
in 57% of patients (Table 2). Trough concentrations did not
differ between patients with either RRT or various degreesTable 1 Characteristics of 42 critically ill patients receiving va
continuous infusion
Characteristic All patients (n = 42) Inte
Age (years) 58 [45 - 66]
Male sex 27 (64.3)
Weight (kg) 70 [61 - 85]
APACHE II score 16 [13 - 25]
SOFA score 6 [3 - 9]
Serum creatinine concentration (μmol/L) 65 [51 - 113]
Urinary creatinine clearance (mL/min.) 85 [60 - 106]
Renal replacement therapy 9 (21.4)
Intermittent hemodialysis 2 (4.8)
Continuous renal replacement therapy 7 (16.7)
Data are described as median [1st - 3rd quartile] or n (%). *Indicates difference betw
acute physiology and chronic health evaluation II; SOFA, sequential organ failure as
than 5.of glomerular filtration (Figure 2) (P = 0.233), but were
more frequently achieved with continuous infusion
therapy (Table 2). Figure 3 illustrates trough con-
centrations according to weight-adjusted daily doses ad-
ministered and stratified for continuous or intermittent
dosing.
The target AUC0–24/MIC (>400) was reached in 71%
of the study subjects if an MIC = 1 mg/L was assumed.
If MIC values of 0.5 or 2 mg/L were used, then the
AUC0–24/MIC (>400) target would have been reached in
88% and 38% of patients, respectively. AUC0–24/MIC
ratios were not statistically significantly different between
patients with RRT or distinct degrees of glomerular filtra-
tion (Figure 4) (P = 0.224). The target AUC0–24/MIC ratio
was more frequently achieved with continuous infusion
therapy (Figure 5) (P = 0.008).
Table 3 describes univariate relationships between
covariates and PD target values as assessed by logistic
regression analyses. Multivariable logistic regression ana-
lysis with adjustment by the propensity score could not
confirm continuous infusion as an independent predictor
of an AUC0–24/MIC >400 (OR 1.65, 95% CI 0.2 to 12.0) or
a Cmin ≥15 mg/L (OR 1.8, 95% CI 0.4 to 8.5). Hosmer
and Lemeshow tests for both models were respectively
P = 0.660 and P = 0.506.
Discussion
This is the first large-scale multicentre point-prevalence
study investigating pharmacokinetics and PK/PD target
attainment of vancomycin in critically ill patients. The
present study revealed that a substantial proportion of
patients did not achieve the target vancomycin expo-
sures. Forty-five percent of patients did not reach the
minimum Cmin threshold (≥15 mg/L) while 26% did not
reach an AUC0–24/MIC ratio >400. The latter index is
generally considered as the most important factor forncomycin therapy, stratified for intermittent dosing or
rmittent dosing (n = 18) Continuous infusion (n = 24) P*
58 [32 - 79] 58 [45 - 66] 0.755
13 (72.2) 14 (58.3) 0.353
75 [65 - 88] 70 [61 - 85] 0.350
17 [14 - 27] 16 [13 - 25] 0.920
5 [3 - 6] 6 [3 - 9] 0.595
64 [52 - 91] 74 [44 - 129] 0.751
72 [20 - 90] 101 [74 - 167] 0.198
1 (5.6) 8 (33.3) NA
0 2
1 6
een intermittent dosing and continuous infusion of vancomycin. APACHE II,
sessment; NA, not applicable as the expected count in at least one cell is less
Table 2 Pharmacokinetic parameters and PK/PD target attainment of vancomycin in critically ill patients
Parameter All patients (n = 42) Intermittent dosing (n = 18) Continuous infusion (n = 24) P*
Vancomycin dose (mg/kg) 27 [18 - 32] 27 [22 - 30] 27 [17 - 33] 0.611
Elimination rate constant (h−1)** 0.09 [0.03 - 0.13] 0.09 [0.03 - 0.13] - -
Clearance (L/h) 3.6 [1.9 - 5.9] 5.1 [2.4 - 7.1] 2.7 [1.7 - 4.1] 0.038
Half-life (h)** 8.2 [5.4 - 24.1] 8.2 [5.4 - 24.1] - -
Cmin (mg/L) 17 [8 - 23] 10 [7- 17] 21 [14 - 26] 0.029
Cmin ≥15 mg/L, n (percentage) 24 (57.1) 7 (38.9) 17 (70.8) 0.038
AUC0–24/MIC 655 [368 - 911] 409 [246 - 712] 830 [529 - 952] 0.029
AUC0–24/MIC > 400, n (percentage) 30 (71.4) 9 (50.0) 21 (87.5) 0.008
Length of vancomycin therapy on sampling date
Days, n 4 [1 - 7] 2 [1 - 6] 4 [1 - 7] 0.314
>2 days, n (percentage) 23/41 (56.1) 8/18 (44.4) 15/23 (65.2) 0.183
>3 days, n (percentage) 22/41 (53.7) 8/18 (44.4) 14/23 (60.9) 0.295
Data are described as median [1st - 3rd quartile] or n (%). For pharmacodynamics calculations, an MIC of 1 mg/L was assumed. *Indicates difference between
intermittent dosing and continuous infusion of vancomycin; **could only be determined in patients receiving intermittent dosing. Cmin, minimum concentration of
drug observed during the dosing period; AUC0–24/MIC, ratio of the area under the concentration-time curve over a 24-hour period divided by the minimum
inhibitory concentration of the suspected bacteria.
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tors have demonstrated that an AUC0–24/MIC ratio above
400 is required to optimise clinical outcomes [4-6]. It has
been proposed that even higher index of exposure might be
necessary in critically ill patients. In a cohort of patients
with MRSA-associated septic shock, Zelenitsky et al. iden-
tified a threshold of AUC0–24/MIC >578 to be associated
with higher likelihood of survival, while an AUC0–24/MIC
<451 was associated with increased odds of death [15].
A threshold AUC0–24/MIC >578 is substantially
higher than the standard cut-off ratio >400. In then=9
n=4
Figure 1 Boxplots of vancomycin dosages administered stratified for
rates. *Data on glomerular filtration were only available in 30 patients. Nopresent study only 24 patients (57%) reached an AUC0–24/
MIC >578.
Another important observation from this study is the
high variability in pharmacokinetics parameters. Wide
ranges in Cmin, AUC0–24, and half-life were observed,
and illustrate the challenge of vancomycin dosing in crit-
ically ill patients in comparison with mild-to-moderately
sick patients in which pharmacokinetics is much
more stable and, as such, predictable [19]. High interpa-
tient variability in pharmacokinetics of antibiotics in
critically ill patients has been reported previouslyn=9
n=8
renal replacement therapy and various glomerular filtration





Figure 2 Boxplot of vancomycin trough concentrations stratified for renal replacement therapy and various glomerular filtration rates.
*Data on glomerular filtration were only available in 30 patients. Red line indicates vancomycin trough concentration target (15 mg/L). No
difference between groups could be demonstrated (P = 0.233).
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agents amikacin and ciprofloxacin proved inadequate
to achieve target peak concentrations in ICU patients
[20,21]. Also standard dosing approaches for beta-lactam
antibiotics appeared to be insufficient to achieve targetFigure 3 Vancomycin trough concentration according to daily dose a
15 mg/L; circles represent patients with continuous infusion; triangles repre
(i) all patients: R = 0.540 (P <0.001), (ii) patients with continuous infusion: R
(P = 0.615).concentrations in the early phase of sepsis [22]. Despite
the generally accepted use of therapeutic drug monitoring
(TDM) in vancomycin therapy and the administration of a
wide range of doses in the present study, dosing was
frequently suboptimal. Besides TDM data, dosing shoulddministered. *Red line indicates target trough concentration of
sent patients with intermittent dosing. Spearman rank correlation for





Figure 4 Boxplot of vancomycin AUC0–24/MIC ratios stratified for renal replacement therapy and various glomerular filtration rates.
*Data on glomerular filtration were only available in 30 patients. Red line indicates the AUC0–24/MIC target ratio (400). No difference between the
groups could be demonstrated (P = 0.224). AUC0–24/MIC, ratio of the area under the concentration-time curve over a 24-hour period divided by
the minimum inhibitory concentration of the suspected bacteria.
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average daily vancomycin doses administered for pa-
tients receiving RRT and patients with a GFR of 51 to
100 mL/min. or >100 mL/min., ranged from 20 to
30 mg/kg (Figure 1), and are therefore in accordanceFigure 5 AUC0–24/MIC ratios of vancomycin for intermittent dosing ve
box), median (band near the middle of the box), and upper quartile (top o
interquartile range from the lower quartile, and the highest value still withi
outliers. The red line indicates the minimum the target threshold for optim
P = 0.029. AUC0–24/MIC, ratio of the area under the concentration-time curve
of the suspected bacteria.with recommendations. Notwithstanding this, more than
half of the patients with GFR 51 to 100 or GFR >100 mL/
min. did not achieve the target trough concentration
of ≥15 mg/L (Figure 2). Particularly in the patient
group with GFR 51 to 100 mL/min. adequate dosingrsus continuous infusion. *Boxes indicate lower quartile (bottom of
f the box); whiskers indicate the lowest value still within 1.5 of the
n 1.5 of the interquartile range from the upper quartile; circles indicate
izing outcomes (AUC0–24/MIC >400). Difference between the groups:
over a 24-hour period divided by the minimum inhibitory concentration
Table 3 Unadjusted relationships with AUC0–24/MIC ratio >400 and target trough concentrations (>15 mg/L)
Variable Unadjusted relationships with AUC0–24/MIC
ratio >400
Unadjusted relationships
with Cmin >15 mg/L
OR (95% CI) P OR (95% CI) P
Age (/year increase) 0.99 (0.95 - 1.03) 0.547 0.99 (0.96 - 1.03) 0.723
Male sex 0.59 (0.13 - 2.69) 0.499 1.20 (0.33 - 4.32) 0.780
SOFA score (/point increase) 1.10 (0.91 - 1.32) 0.318 1.05 (0.91 - 1.21) 0.519
Renal replacement therapy 3.64 (0.40 - 33.12) 0.252 3.29 (0.59 - 18.3) 0.173
Fluid balance of the latest 24 hours
Negative fluid balance 2.20 (0.49 - 9.88) 0.305 1.12 (0.32 - 3.91) 0.856
Negative fluid balance >1000 mL 2.40 (0.26 - 22.55) 0.444 1.00 (0.19 - 5.15) 0.999
Positive fluid balance 0.46 (0.10 - 2.05) 0.305 0.89 (0.26 - 3.10) 0.856
Positive fluid balance >1000 mL 0.46 (0.11 - 1.85) 0.273 0.75 (0.22 - 2.60) 0.650
Positive fluid balance >2000 mL 0.23 (0.05 - 1.06) 0.059 0.68 (0.16 - 2.85) 0.602
Serum creatinine, mg/dL (/mg increase) 1.02 (0.71 - 1.48) 0.914 2.71 (0.78 - 9.37) 0.116
Creatinine clearance, mL/min. (/mL increase) 1.02 (0.99 - 1.04) 0.194 1.00 (0.98 - 1.01 0.457
Infection source pneumonia or intra-abdominal infection 2.84 (0.52 - 15.47) 0.227 4.2 (0.97 - 18.53) 0.056
Vancomycin dose, mg/kg (/mg increase) 1.03 (0.97 - 1.10) 0.319 1.06 (0.99 - 1.14) 0.071
Continuous infusion of vancomycin 11.00 (1.98 - 61.26) 0.006 3.82 (1.05 - 13.91) 0.042
Length of vancomycin therapy at sampling date
Days (/day increase) 1.35 (1.02 - 1.79) 0.034 0.94 (0.82 - 1.08) 0.370
>2 days 10.50 (1.88 - 58.62) 0.007 1.56 (0.45 - 5.41) 0.487
>3 days 9.00 (1.63 - 49.76) 0.012 1.30 (0.38 - 4.49) 0.687
AUC0–24/MIC, ratio of the area under the concentration-time curve over a 24-hour period divided by the minimum inhibitory concentration of the suspected bacteria;
Cmin, minimum concentration of drug observed during the dosing period; OR, odds ratio; CI, confidence interval; SOFA, sequential organ failure assessment.
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and high variability despite reasonable dosages admi-
nistered. In patients with more impaired renal function
(GFR 0 to 30 mL/min.) doses were restricted (median
10 mg/kg), also leading to inadequate trough concentra-
tions in half of the patients. Patients receiving RRT most
frequently achieved satisfying trough concentrations.
In the present study, continuous infusion of vanco-
mycin appeared more successful for reaching target PD
parameters than intermittent dosing (Tables 2 and 3).
However, logistic regression failed to confirm this rela-
tionship. Continuous infusion of vancomycin in critically
ill patients has been advocated before [23,24]. Although
not recommended by the guidelines for the treatment of
S. aureus infections or vancomycin therapy [2,3], the
agent appears to be increasingly administered by continu-
ous infusion. The present data cannot underscore the
value of continuous infusion therapy for more consistently
achieving PK/PD targets in this group of patients. Yet,
previous reports stressed the potential value of conti-
nuously infused vancomycin stating that it may result in
faster achievement of target concentrations [25], as well as
more stable drug concentrations [26,27]. Although it
seems reasonable to assume more favourable outcomes
when PK/PD is optimised, clinical outcome data favouringcontinuous infusion are far from conclusive. In a cohort of
patients with ventilator-associated pneumonia, Rello et al.
found lower mortality rates in patients receiving vanco-
mycin by continuous infusion (25% vs. 55%; P = 0.03) [28].
Although this finding was confirmed by logistic regression
analysis, it should be interpreted cautiously as the study
was primarily not designed for this purpose [24].
This point-prevalence study shows that vancomycin
dosing practice results in too many patients being un-
derdosed even with the availability of TDM. In order to
overcome the risk of inadequate concentrations, new
approaches should be considered such as the use of
weight-based loading doses [13] as well as administra-
tion by continuous infusion. In one study by De Waele
et al., administering a loading dose of 1000 mg (<65 kg) or
1500 mg (>65 kg) followed by a continuous infusion of
2000 mg/24 h, the authors found that 78% and 88% of crit-
ically ill patients reached a serum concentration ≥15 mg/L
on day two and three respectively [29]. In a dosing simu-
lation analysis, Roberts et al. demonstrated that at least
35 mg/kg/24 h administered by continuous infusion is
needed to maintain a concentrations ≥20 mg/L in some
patients [13]. Alternatively, some authors have proposed
the use of a vancomycin dosing nomogram for ICU pa-
tients. One recent nomogram that takes into account body
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Modification of Diet in Renal Disease equation for dosing
frequency [30]. Although the nomogram resulted in a
significant increase in patients achieving the target trough
concentration, still 28% of patients had sub-therapeutic
vancomycin exposures. Given the high variability in
vancomycin concentrations, TDM should be considered
essential, but as shown from this data, does not guarantee
achievement of target concentrations.
This study has some limitations. First, we could not
evaluate clinical outcome data as only nine patients had
documented Gram-positive infections, the remaining
patients were administered empiric therapy. However,
this data does provide good insight into the PK/PD
exposures of vancomycin that occur with contempor-
ary dosing approaches. Second, PD calculations used
assumed MIC values. For detailed analyses an assumed
MIC = 1 mg/L was used because in Europe only 8% of
S. aureus MICs for vancomycin are >1 mg/L [31]. Third,
no data about potential loading doses were available.
Conclusions
In conclusion, this study demonstrated large variability in
vancomycin pharmacokinetics and PK/PD target attain-
ment in critically ill patients. Continuous infusion was asso-
ciated with higher likelihood to achieving clinically relevant
trough concentrations (of ≥15 mg/L) pharmacodynamic ex-
posure (AUC0–24/MIC ratio >400) in univariate analyses
but not in multivariate analyses. These data support a re-
evaluation of vancomycin dosing recommendations in crit-
ically ill patients with new approaches to more rapidly and
consistently achieve clinically relevant PK/PD targets.
Key messages
 We analysed vancomycin concentrations from
42 patients across 26 ICUs in eight countries.
The indication for vancomycin was empiric
(not directed) in 74% of cases.
 A total of 57% of patients were administered
vancomycin by continuous infusion, although
there was no difference in dose with
patients administered intermittent dosing
(27 mg/kg/day).
 Only 57% of patients achieved the target
concentration (≥15 mg/L) and only 71% achieved
a target AUC0–24/MIC of 400 (assuming a MIC
of 1 mg/L).
 Although univariate analysis showed therapeutic
targets were more consistently achieved with
continuous infusion compared with intermittent
dosing (P = 0.008), in multivariable logistic
regression with adjustment by propensity score,
this statistical significance was not maintained.Additional files
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